 Gastrointestinal Agents
"Gastrointestinal Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
| Descriptor ID |
D005765
|
| MeSH Number(s) |
D27.505.954.483
|
| Concept/Terms |
Gastrointestinal Agents- Gastrointestinal Agents
- Agents, Gastrointestinal
- Gastrointestinal Drugs
- Drugs, Gastrointestinal
Gastric Agents- Gastric Agents
- Agents, Gastric
- Gastric Drugs
- Drugs, Gastric
|
Below are MeSH descriptors whose meaning is more general than "Gastrointestinal Agents".
Below are MeSH descriptors whose meaning is more specific than "Gastrointestinal Agents".
This graph shows the total number of publications written about "Gastrointestinal Agents" by people in this website by year, and whether "Gastrointestinal Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 1 | 1 | 2 | | 2007 | 0 | 2 | 2 | | 2008 | 3 | 0 | 3 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 1 | 2 | | 2012 | 1 | 0 | 1 | | 2014 | 3 | 0 | 3 | | 2016 | 1 | 2 | 3 | | 2017 | 0 | 3 | 3 | | 2019 | 4 | 1 | 5 | | 2020 | 2 | 2 | 4 | | 2021 | 2 | 4 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Gastrointestinal Agents" by people in Profiles.
-
Shen B, Kochhar GS, Rubin DT, Kane SV, Navaneethan U, Bernstein CN, Cross RK, Sugita A, Schairer J, Kiran RP, Fleshner P, McCormick JT, D'Hoore A, Shah SA, Farraye FA, Kariv R, Liu X, Rosh J, Chang S, Scherl E, Schwartz DA, Kotze PG, Bruining DH, Philpott J, Abraham B, Segal J, Sedano R, Kayal M, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sehgal P, Picoraro JA, Vermeire S, Sandborn WJ, Silverberg MS, Pardi DS. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
-
Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. Clin Gastroenterol Hepatol. 2022 05; 20(5):1059-1067.e9.
-
Pabla BS, Alex Wiles C, Slaughter JC, Scoville EA, Dalal RL, Beaulieu DB, Schwartz DA, Horst SN. Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor a Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience. Dig Dis Sci. 2022 07; 67(7):3129-3137.
-
Shah RS, Bachour S, Jia X, Holubar SD, Hull TL, Achkar JP, Philpott J, Qazi T, Rieder F, Cohen BL, Regueiro MD, Lightner AL, Click BH. Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection. J Crohns Colitis. 2021 Jul 05; 15(7):1142-1151.
-
Hanna P, Regmi S, Kalapara A, Mulpuri KS, Zabell J, Albersheim J, Wahr J, Randle D, Kaizer A, Patten L, Konety B, Weight C. Alvimopan as part of the Enhanced Recovery After Surgery protocol following radical cystectomy is associated with decreased hospital stay. Int J Urol. 2021 06; 28(6):696-701.
-
Constant BD, Khushal S, Jiang J, Bost JE, Chaisson E, Conklin LS. Early Inflammatory Markers are Associated With Inadequate Post-Induction Infliximab Trough in Pediatric Crohn's Disease. J Pediatr Gastroenterol Nutr. 2021 03 01; 72(3):410-416.
-
Lewis CV, Taylor WR. Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease. Am J Physiol Heart Circ Physiol. 2020 12 01; 319(6):H1227-H1233.
-
Karpen SJ, Kelly D, Mack C, Stein P. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020 Sep; 14(5):677-689.
-
Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2020 Jun 19; 14(5):575-587.
-
Franco DL, Click B. Proactive Versus Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: Is the Juice Worth the Squeeze? Inflamm Bowel Dis. 2020 01 01; 26(1):112-113.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|